2Ferreri A J,Abrey L E,Blay J Y,et al.Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma,Lugano Switzerland,June 12-15,2002.J Clin Oncol,2003,21:2407-2414.
3Nakamura M,Shimada K,Ishida E,et al.Histopathology,pathogenesis and molecular genetics in primary central nervous system lymphomas.Histol Histopathol,2004,19:211-219.
4Deangellis LM.Primary central nervous system lymphoma:treatment with combined chemotherapy and radiotherapy.J Neurooncol,1999,43:249-257.
6Ferreri AJ,Blay JY,Reni M,et al.Prognostic scoring system for primary CNS lymphomas:the International Extranodal Lymphoma Study Group experience.J Clin Oncol,2003,21:266-272.
7Kraemer DE,Fortin D,Doolittle ND,et al.Association of total dose intensity of chemotherapy in primary central nervous system lymphlma and survival.Neurosurg,2001,48:1033-1041.
8Mcallister LD,Doolittle ND,Guastadisegni PE,et al.Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.Neurosurgery,2000,46:51-61.
9Reni M,Gruber ML,Cher L,et al.Preirradiation methotrexate chemotherapy of primary malignant non-Hodgkin' s lymphoma of the central nrvous system:Preliminary data.Ann Oncol,1997,8:227-234.
10Angelis LM , Seiferheld W , Schold SC, et al .Combined modality treatment of primary central nervous system lymphoma (PSNSK):RTDG 93～10[J].Proc Am Soc Clin Oncol,1999,18:140.
